The largest database of trusted experimental protocols

7 protocols using magnesium stearate

1

Probiotic Tablet Formulation by Direct Compression

Check if the same lab product or an alternative is used in the 5 most similar protocols
The probiotic tablets were produced by direct compression using a single punch tablet press (MCC Corporation, NJ, US) fitted with a flat-faced bevel-edged punches with diameter of 8 mm. The probiotic powder blends consisted of 10% (w/w) spray-dried bacterial powder, 85% (w/w) filler-binder and 5% (w/w) magnesium stearate (magnesium stearate; Fagron, Nazareth, Belgium). The used direct compression filler-binders were Tablettose  100 (lactose; Meggle Pharma, Wasserburg, Germany) and Xylisorb  XTAB 240 (xylitol; Roquette pharma, Zaventem, Belgium). These filler-binders were chosen based on the results of previously investigations (Byl et al., 2019b (Byl et al., , 2019a)) . The high concentration of lubricant was selected to avoid sticking to punches and die. To investigate the effect of the compression pressure on bacterial survival, the bacterial powder blends were compacted at different pressures, namely from 40 until 120 MPa.
+ Open protocol
+ Expand
2

Cetirizine Formulation Development and Evaluation

Check if the same lab product or an alternative is used in the 5 most similar protocols
The active substance used was cetirizine dihydrochloride (Jubilant Lifesciences Ltd, India; CTZ). The excipients used for the study SeDeM were talc (Fagron, Spain), magnesium stearate (Fagron, Spain), and colloidal silicon dioxide (Aerosil ®, Fagron, Spain). The excipients used in the factorial design were mannitol (Fagron, Spain) and polyvinylpyrrolidone Ph. Eur (Fagron, Spain). The reagents used for the preparation of phosphate buffers solutions (solubility studies) were: 37% HCl (Panreac, Barcelona), NaCl (Panreac, Barcelona), NaOH (Panreac, Barcelona) and KH2PO4 (Panreac, BCN).
+ Open protocol
+ Expand
3

Tolcapone Formulation Development and Evaluation

Check if the same lab product or an alternative is used in the 5 most similar protocols
The active substance under study is tolcapone (batches: SOM0114599 and SOM0714600) (CCN Industries LTD via Porschem Pharm).
The excipients studied are Vivapur® 102 (JRS, Rosenberg, Germany), Avicel® PH 101 (FMC Corp, Brusseles, Belgium), Kleptose® (ROQUETTE, Roquette Frères, Lestrem, France), Kollidon® VA 64 (BASF, Ludwigshafen, Germany), Prosolv® HD90 (JRS, Rosenberg, Germany), Isomalt® 721 (GalenIQ, Manheim, Germany), Methocel® K100M CR (Colorcon, Dartford, UK), talc (Fagron, Terrassa, Spain), magnesium stearate (Fagron, Terrassa, Spain), and colloidal silicon dioxide (Fagron, Terrassa, Spain).
+ Open protocol
+ Expand
4

Antioxidant Activity Assessment of Melatonin Formulation

Check if the same lab product or an alternative is used in the 5 most similar protocols
Melatonin was purchased from Methapharmaceutical IND S.L. (Spain). Mannitol, polyvinylpyrrolidone (crospovidone), lactose, magnesium stearate, anhydrous colloidal silica, tartaric acid and sodium bicarbonate were all supplied by Fagron Ibérica S.A.U. (Spain).
The antioxidants, vitamin C (sodium ascorbyl phosphate) and resveratrol were supplied by Fagron Ibérica S.A.U. (Spain). NADPH, adenosine triphosphate (ATP) and glutathione (GSH) were purchased from Sigma Aldrich (Spain).
For the determination of total antioxidant activity using the ferric ion reducing antioxidant power (FRAP) technique, the following were used: sodium acetate, acetic acid, 2,4,6-tris(2-pyridyl)-s-triazine (TPTZ), hydrochloric acid, ferric chloride, FeSO4 × 7 H2O and bidistilled water, purchased from Sigma Aldrich (Spain).
For the determination of total antioxidant activity using the TAC technique, the following were used: sodium acetate, bidistilled water, glacial acetic acid, hydrogen peroxide, 2,2’-azino-bis-2-ethybenzothiazoline-6-sulphonic acid (ABTS), the water-soluble analogue of vitamin E (Trolox (6-hydroxy-2,5,7,8-tetramethylchroman-2-carboxylic acid)), ethanol, methanol and monosodium phosphate, purchased from Sigma Aldrich (Spain).
+ Open protocol
+ Expand
5

Analytical Method Development and Validation

Check if the same lab product or an alternative is used in the 5 most similar protocols
Caffeine, croscarmellose, and lactose monohydrate were supplied by Caelo (Hilden, Germany). Polyvinylpyrrolidone (PVP) 90, magnesium stearate, silica dioxide, and hydroxypropyl methylcelluose K4M (HPMC) were purchased from Fagron (Barsbüttel, Germany).
Water HiPerSolv CHROMANORM LC-MS grade (VWR international, Fontenay-sous-Bois, France), Methanol HiPerSolv CHROMANORM LC-MS grade (VWR international, Fontenay-sous-Bois, France), Formic acid (Merck KaA Gmbh, Darmstadt, Germany), Acetonitrile HiPerSolv CHROMANORM LC-MS grade (VWR international, Fontenay-sous-Bois, France), ammonium acetate (Merck KaA Gmbh, Darmstadt, Germany), completely desalinated water (based on tap water, Stadtwerke Greifswald, Germany, prepared by double reverse osmosis).
+ Open protocol
+ Expand
6

Carbamazepine Formulation Development

Check if the same lab product or an alternative is used in the 5 most similar protocols
The active pharmaceutical ingredient (API) used was carbamazepine (batches: 16CT000089 and 16CT000017), obtained from CTX Lifesciences Pvt. Limited, India.
The main excipients used were: l-HPC LH11 [(low-substituted hydroxypropylcellulose) (supplier: SHINETSU, Tokyo, Japan)]; l-HPC NBD022 [(low substituted hydroxypropyl cellulose) (supplier: SHINETSU, Tokyo, Japan)].
The adjuvant excipients used were: VIVASOL GF® [(croscarmellose) (batch: 7111601027, supplier: JRS PHARMA, Rosenberg, Germany)]; VIVAPHARM PVP PXL® [(crospovidone type A) (supplier: JRS PHARMA, Rosenberg, Germany)]; VIVAPHARM PVP PXL10® [(Crospovidone Type B) (supplier: JRS PHARMA, Rosenberg, Germany)]; PEARLITOL 200 SD® [(d-Mannitol) (supplier: ROQUETTE LAISA ESPAÑA, Valencia, Spain)]. The excipients used as lubricants and ligants were: Talc (supplier: Fagron, Barcelona, Spain); magnesium stearate (supplier: Fagron, Barcelona, Spain) and colloidal silicon dioxide (Aerosil®) (supplier: Fagron, Barcelona, Spain) as a standard lubrication blend. All components were stored at room temperature (20–30 °C).
+ Open protocol
+ Expand
7

Formulation of Probiotic Throat Lozenges

Check if the same lab product or an alternative is used in the 5 most similar protocols
Freeze-dried Lactobacillus rhamnosus GG (ATCC31103) was provided to us as THT 030903 by THT (Gembloux, Belgium). Subsequently, probiotic tablets were made as powder blends of freeze-dried LGG, a direct compression filler-binder and a suitable amount of lubricant to void sticking to punches and die (magnesium stearate; Fagron, Nazareth, Belgium). To target the probiotic bacteria at the pharyngeal microbiome, the probiotic bacteria were processed into a throat lozenge and an orally disintegrating tablet. Direct compression filler-binders that are suitable for these pharmaceutical dosage forms were selected and analyzed. The studied filler-binders, which are listed in table 1, were chosen to represent a range of materials with different compression behaviors (plastically or elastically deformation, fragmenting). [Table 1 near here]
+ Open protocol
+ Expand

About PubCompare

Our mission is to provide scientists with the largest repository of trustworthy protocols and intelligent analytical tools, thereby offering them extensive information to design robust protocols aimed at minimizing the risk of failures.

We believe that the most crucial aspect is to grant scientists access to a wide range of reliable sources and new useful tools that surpass human capabilities.

However, we trust in allowing scientists to determine how to construct their own protocols based on this information, as they are the experts in their field.

Ready to get started?

Sign up for free.
Registration takes 20 seconds.
Available from any computer
No download required

Sign up now

Revolutionizing how scientists
search and build protocols!